Regeneron Embarks on Phase 3 Covid-19 Prevention Trial
July 06 2020 - 7:48AM
Dow Jones News
By Matt Grossman
Regeneron Pharmaceuticals Inc. is initiating a Phase 3 trial for
its double antibody cocktail to determine whether the cocktail can
prevent Covid-19, the Tarrytown, N.Y.-based company said
Monday.
The trial will evaluate whether Regeneron's cocktail, called
REGN-COV2, can prevent infection among people who have had close
exposure to the coronavirus that causes the disease.
Regeneron's trial will enroll 2,000 patients at approximately
U.S. 100 sites.
The company has also moved into the Phase 2/3 portion of trials
testing the cocktail's ability to treat people who have already
contracted Covid-19. That effort will enroll approximately 2,900
patients, including hospitalized and non-hospitalized patients, at
150 sites in the U.S., Brazil, Mexico and Chile.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
July 06, 2020 07:33 ET (11:33 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024